| Literature DB >> 35054145 |
Olga Vriz1,2, Paolo Palatini3, Lawrence Rudski4, Paolo Frumento5, Jarosław D Kasprzak6, Francesco Ferrara7, Rosangela Cocchia8, Luna Gargani9, Karina Wierzbowska-Drabik6, Valentina Capone8, Brigida Ranieri10, Andrea Salzano10, Anna Agnese Stanziola11, Alberto Maria Marra12, Roberto Annunziata8, Salvatore Chianese8, Salvatore Rega12, Teresa Saltalamacchia12, Renato Maramaldi12, Chiara Sepe8, Giuseppe Limongelli13, Filippo Cademartiri10, Antonello D'Andrea14, Michele D'Alto13, Raffaele Izzo15, Nicola Ferrara12, Ciro Mauro9, Antonio Cittadini12, Grünig Ekkehard16, Marco Guazzi17, Eduardo Bossone8.
Abstract
BACKGROUND: Systemic arterial hypertension (HTN) is the main risk factor for the development of heart failure with preserved ejection fraction (HFpEF). The aim of the study was was to assess the trends in PASP, E/E' and TAPSE during exercise Doppler echocardiography (EDE) in hypertensive (HTN) patients vs. healthy subjects stratified by age.Entities:
Keywords: echocardiography stress test; left ventricular diastolic dysfunction; pulmonary pressure
Year: 2022 PMID: 35054145 PMCID: PMC8778233 DOI: 10.3390/jcm11020451
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
General characteristics in normal and hypertensive subjects.
| Normotensive | Hypertensive | ANOVA Adjusted by Age, Sex, BSA | ||
|---|---|---|---|---|
| Age (years) | 54 ± 14.9 | 62 ± 12.0 | 0.0001 | - |
| M/F | 65/58 | 113/42 | 0.01 | - |
| BMI (Kg/m2) | 26 ± 3.5 | 27.8 ± 4 | 0.0001 | - |
| BSA (m2) | 1.97 ± 0.1 | 1.89 ± 0.2 | 0.0001 | |
| SBP (mmHg) | 123 ± 16 | 137 ± 20 | 0.0001 | 0.0001 |
| DBP (mmHg) | 77 ± 10 | 82 ± 11 | 0.0001 | 0.0001 |
| HR (bpm) | 75 ± 15 | 73 ± 13 | 0.1 | 0.7 |
| Hemoglobin (dL/L) | 14.6 ± 1.8 | 14.4 ± 1.7 | 0.3 | 0.0001 |
| Creatinine (mg/dL) | 0.97 ± 0.18 | 1.0 ± 0.22 | 0.2 | 0.9 |
| Glucose (mg/dL) | 110 ± 48 | 117 ± 40 | 0.4 | 0.039 |
| Tot Chol (mg/dL) | 198 ± 38 | 177 ± 52 | 0.07 | 0.002 |
| HDL (mg/dL) | 52 ± 13 | 49 ± 12 | 0.3 | 0.001 |
| Triglycerides (mg/dL) | 117 ± 70 | 119 ± 62 | 0.9 | 0.006 |
Abbreviations: BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure; HR, heart rate; M/F, Male/Female; SBP, systolic blood pressure.
Baseline echocardiographic variables in normotensive and hypertensive subjects.
| Normotensive | Hypertensive | ANOVA Adjusted by Age, Sex, BSA | ||
|---|---|---|---|---|
| LVIDD (mm) | 47.0 ± 3.9 | 48.0 ± 7.0 | 0.1 | 0.0001 |
| IVSD (mm) | 9.7 ±1.2 | 10.0 ± 2.0 | 0.0001 | 0.0001 |
| PWTD (mm) | 9.2 ± 1.3 | 9.2 ± 1.7 | 0.4 | 0.0001 |
| LVM (gr) | 153.0 ± 36 | 174.8 ± 69 | 0.001 | 0.0001 |
| LVMI (gr/m2) | 81.9 ± 17 | 91.8 ± 31 | 0.001 | 0.015 |
| RWT | 0.35 ± 0.08 | 0.39 ± 0.09 | 0.0001 | 0.0001 |
| LVEF (%) | 64.0 ± 7.0 | 63.0 ± 9.0 | 0.1 | 0.023 |
| LAVi (vol/BSA) | 22.8 ± 8 | 26.1 ± 11.7 | 0.01 | 0.0001 |
| E/A | 1.20 ± 0.5 | 1.17 ± 0.5 | 0.2 | 0.0001 |
| E/E’ | 7.3 ± 2.5 | 8.8 ± 3.2 | 0.0001 | 0.0001 |
| SV (mL) | 69.7 ± 16 | 71.0 ± 20 | 0.6 | 0.003 |
| CO (mL/min) | 5.1 ± 1.4 | 5.1 ± 1.7 | 0.7 | 0.001 |
| CI (mL/min/m2) | 2.8 ± 0.8 | 2.7 ± 0.8 | 0.4 | 0.27 (*) |
| TAPSE (mm) | 23.0 ± 3.0 | 23.0 ± 3.7 | 0.9 | 0.1 |
| PASP (mmHg) | 22.0 ± 3.0 | 25.0 ± 7.0 | 0.0001 | 0.0001 |
| mPAP (mmHg) | 15.4 ± 3.1 | 17.2 ± 4.2 | 0.0001 | 0.0001 |
| PASP/CI | 4.7 ± 2.2 | 10.2 ± 4.3 | 0.0001 | 0.0001 (*) |
| TAPSE/PASP (mm/mmHg) | 1.2 ± 0.4 | 1.06 ± 0.3 | 0.04 | 0.0001 |
| RVOT-AccTime (ms) | 143 ± 27 | 127 ± 26 | 0.0001 | 0.0001 |
| PVR (WU) | 1.27 ± 0.4 | 1.6 ± 0.6 | 0.0001 | 0.008 |
Abbreviations: CI, left ventricular cardiac output index; CO, left ventricular cardiac output; AccTime, acceleration time; E/A, transmitral flow ratio; E/E’, E wave and E’ wave on TDI ratio; IVSD, interventricular septum in systole; LAVi, left atrial volume index; LV left ventricular mass; LVEF, left ventricular ejection fraction; LVIDD, left ventricular internal diameter in diastole; LVM, left ventricular mass; LVMI, left ventricular mass index; mPAP, mean pulmonary artery pressure; PASP, pulmonary arterial systolic pressure; PVR, pulmonary vascular resistances; PWTD, posterior wall thickness in diastole; RVOT-AccTime, acceleration time on RVOT (right ventricular outflow tract); RWT, relative wall thickness; SV, left ventricular stroke volume; TAPSE, tricuspid annular systolic excursion; TAPSE/PASP, tricuspid annular systolic excursion/ pulmonary systolic arterial. (*) no BSA.
Difference between normotensive and hypertensive subjects at peak stress test.
| Normotensive | Hypertensive | ANOVA Adjusted by Age, Sex, BSA | ||
|---|---|---|---|---|
| Watts (peak) | 133 ± 38 | 104 ± 35 | 0.0001 | 0.0001 |
| Time Exe (min) | 10.4 ± 3.0 | 8.4 ± 2.8 | 0.0001 | 0.0001 |
| SBP (mmHg) | 188 ± 29 | 165 ± 24 | 0.0001 | 0.0001 |
| DBP (mmHg) | 96 ± 17 | 91 ± 13 | 0.047 | 0.02 |
| HR (bpm) | 138 ± 18 | 123 ± 19 | 0.0001 | 0.0001 |
| LVEF (%) | 71 ± 8.1 | 69 ± 11 | 0.09 | 0.0001 |
| E/E’ | 6.6 ± 2.9 | 10.7 ± 5.5 | 0.0001 | 0.0001 |
| SV (mL) | 89 ± 20 | 86 ± 26 | 0.1 | 0.007 |
| CO peak-rest (mL/min) | 7.2 ± 2.8 | 5.2 ± 3.5 | 0.0001 | 0.0001 |
| CO (mL/min) | 12.5 ± 3.1 | 10.6 ± 3.6 | 0.0001 | 0.0001 |
| CI (mL/min/m2) | 6.6 ± 1.7 | 5.6 ± 1.8 | 0.0001 | 0.0001 (*) |
| TAPSE (mm) | 28.3 ± 3.4 | 28.4 ± 5.2 | 0.7 | 0.0001 |
| PASP (mmHg) | 35.4 ± 9.4 | 47.3 ± 13.9 | 0.0001 | 0.0001 |
| PASP peak-rest | 13.6 ± 9.1 | 22.7 ± 13.7 | 0.0001 | 0.0001 |
| mPAP (mmHg) | 23 ± 5.8 | 31 ± 8.5 | 0.0001 | 0.0001 |
| PASP/W | 3.1 ± 1.4 | 5.1 ± 2.4 | 0.0001 | 0.0001 |
| PASP/CI | 5.8 ± 3.4 | 9.4 ± 4.6 | 0.0001 | 0.0001 (*) |
| TAPSE/PASP (mm/mmHg) | 0.94 ± 0.2 | 0.65 ± 0.2 | 0.0001 | 0.0001 |
| RVOT-AccTime (ms) | 142.8 ± 33 | 116 ± 24 | 0.0001 | 0.0001 |
| PVR (WU) | 1.38 ± 0.5 | 1.74 ± 0.5 | 0.0001 | 0.0001 |
(*) no BSA.
Hypertensive patient characteristics divided by age.
| Group 1 | Group 2 | Group 3 | ANOVA | ANOVA Adjusted by Age, Sex, BSA | |
|---|---|---|---|---|---|
| LVIDD (mm) | 47.0 ± 3.9 | 48.0 ± 7.0 | 0.1 | 0.0001 | |
| Age (years) | 43 ± 8 | 59.6 ± 4.4 | 73.5 ± 4.4 | 0.0001 | |
| M/F | 24/4 | 48/17 | 41/21 | 0.1 | - |
| BMI | 27 ± 5 | 28.4 ± 4 | 27 ± 3.8 | 0.2 | - |
| BSA (m2) | 1.95 ± 0.2 | 1.9 ± 0.2 | 1.83 ± 0.2 | 0.004 | - |
| SBP (mmHg) | 142 ± 22 | 136 ± 21 | 136 ± 18 | 0.3 | 0.0001 |
| DBP (mmHg) | 87.9 ± 13 | 83 ± 12 | 78.4 ± 8 | 0.002 | 0.0001 |
| HR (bpm) | 69.9 ± 13 | 74 ± 12 | 73 ± 13 | 0.4 | 0.002 |
| Therapy (no/yes) | 15/13 | 15/50 | 4/58 | 0.0001 | 0.0001 (*) |
| Hemoglobin (dL/L) | 15 ± 1.7 | 14.4 ± 1.4 | 13.8 ± 1.9 | 0.02 | 0.0001 |
| Creatinine (mg/dL) | 0.98 ± 0.17 | 1.01 ± 0.19 | 1 ± 0.3 | 0.8 | 0.5 |
| Glucose (mg/dL) | 102 ± 22 | 124 ± 46 | 120 ± 41 | 0.1 | 0.11 |
| Tot Chol (mg/dL) | 190 ± 45 | 173 ± 62 | 157 ± 47 | 0.08 | 0.09 |
| HDL (mg/dL) | 51 ± 11 | 49 ± 11 | 50 ± 13 | 0.5 | 0.6 |
| Triglycerides (mg/dL) | 104 ± 59 | 137 ± 68 | 102 ± 49 | 0.6 | 0.018 |
Abbreviations: M/F, male/female; BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure. No adjusted by therapy (*).
Baseline echocardiographic characteristics in hypertensive patients divided into 3 groups of age.
| Group 1 | Group 2 | Group 3 | ANOVA | ANOVA Adj by Sex BSA, Therapy | |
|---|---|---|---|---|---|
| LVIDD (mm) | 49 ± 4.7 | 48 ± 8.5 | 47 ± 6.4 | 0.3 | 0.1 |
| IVSD (mm) | 9.6 ±2.0 | 10.4 ± 2.3 | 10.8 ± 1.7 | 0.036 | 0.025 |
| PWTD (mm) | 9.4 ± 2 | 9.1 ± 1.7 | 9.3 ± 1.5 | 0.1 | 0.9 |
| LVM (gr) | 176 ± 44 | 177 ± 89 | 171 ± 55 | 0.2 | 0.09 |
| LVMI (gr/m2) | 89 ± 20 | 91 ± 40 | 93 ± 25 | 0.1 | 0.1 (*) |
| RWT | 0.39 ± 0.1 | 0.39 ± 0.1 | 0.40 ± 0.09 | 0.6 | 0.3 |
| LVEF (%) | 62 ± 8.5 | 64 ± 8 | 61 ± 9 | 0.07 | 0.6 |
| LAi (vol/BSA) | 21 ± 5.6 | 23.6 ± 9.9 | 29.4 ± 13 | 0.006 | 0.9 (*) |
| E/A | 1.5 ± 0.7 | 1.2 ± 0.3 | 1.03 ± 0.3 | 0.0001 | 0.1 |
| E/E’ | 6.7 ± 2.2 | 8.5 ± 3.2 | 10 ± 2.9 | 0.0001 | 0.0001 |
| SV (mL) | 69 ± 18 | 73 ± 23 | 69 ± 18 | 0.001 | 0.001 |
| CO (L/min) | 4.8 ± 1.5 | 5.4 ± 1.7 | 5.0 ± 1.7 | 0.8 | 0.03 |
| CI (mL/min/m2) | 2.5 ± 0.8 | 2.7 ± 0.8 | 2.7 ± 0.9 | 0.5 | 0.2 (*) |
| TAPSE (mm) | 23.5 ± 3.7 | 23 ± 3.2 | 23 ± 4.2 | 0.7 | 0.001 |
| PASP (mmHg) | 22.2 ± 5.9 | 24.2 ± 5.7 | 26.6 ± 8.1 | 0.017 | 0.7 |
| mPAP (mmHg) | 15.9 ± 3.4 | 17.8 ± 3.7 | 17.6 ± 5 | 0.036 | 0.28 |
| PASP/CI | 9.7 ± 3.2 | 9.7 ± 3.9 | 10.9 ± 5.0 | 0.4 | 0.7 (*) |
| TAPSE/PASP (mm/mmHg) | 1.1 ± 0.3 | 1.07 ± 0.3 | 1.02 ± 0.3 | 0.3 | 0.07 |
| RVOT-AccTime (ms) | 132 ± 23 | 127 ± 24 | 124 ± 26 | 0.09 | 0.2 |
| PVR (WU) | 1.61 ± 0.6 | 1.6 ± 0.5 | 1.6 ± 0.6 | 0.8 | 0.4 |
Abbreviations: AccTime, acceleration time; CI, left ventricular cardiac output index; CO, left ventricular cardiac output; E/A, transmitral flow ratio; E/E’, E wave and E’ wave on TDI ratio; IVSD, interventricular septum in systole; LAVi, left atrial volume index; LVEF, left ventricular ejection fraction; LVIDD, left ventricular internal diameter in diastole; LV left ventricular mass; LVMI, left ventricular mass index; mPAP, mean pulmonary artery pressure; PASP, pulmonary arterial systolic pressure; PWTD, posterior wall thickness in diastole; RWT, relative wall thickness; PVR, pulmonary vascular resistances; RVOT-AccTime, acceleration time on RVOT (right ventricular outflow tract); SV, left ventricular stroke volume; TAPSE, tricuspid annular systolic excursion; TAPSE/PASP, tricuspid annular systolic excursion/pulmonary systolic arterial. (*) no BSA.
Hypertensive patient characteristics at peak stress divided by age.
| Group 1 | Group 2 | Group 3 | ANOVA | ANOVA Adj by Sex, BSA, Therapy | |
|---|---|---|---|---|---|
| Watts (peak) | 120 ± 33 | 100 ± 32 | 93 ± 35 | 0.0001 | 0.001 |
| Time Exe (min) | 5.2 ± 1.2 | 4.3 ± 1.3 | 3.6 ± 1.3 | 0.0001 | 0.001 |
| SBP (mmHg) | 175 ± 28 | 169 ± 27 | 158 ± 19 | 0.1 | 0.2 |
| DBP (mmHg) | 104 ± 15 | 95 ± 14 | 84 ± 8 | 0.0001 | 0.5 |
| HR (bpm) | 133 ± 16 | 127.3 ± 16 | 113 ± 19 | 0.0001 | 0.001 |
| LVEF (%) | 74 ± 9.5 | 69 ± 10 | 65 ± 12 | 0.01 | 0.001 |
| E/E’ | 7.5 ± 2.0 | 9.7 ± 6.0 | 13.0 ± 4.6 | 0.005 | 0.0001 |
| SV (mL) | 89.0 ± 29.0 | 88.7 ± 25.0 | 82.0 ± 27.0 | 0.4 | 0.0001 |
| CO peak-rest | 7.1 ± 3.8 | 5.5 ± 3.0 | 4.4 ± 3.3 | 0.005 | 0.0001 |
| CO (L/min) | 12.0 ± 3.5 | 11.3 ± 3.4 | 9.3 ± 3.5 | 0.0001 | 0.0001 |
| CI (L/min/m2) | 6.1 ± 1.7 | 5.8 ± 1.7 | 5.5 ± 1.7 | 0.007 | 0.0001 (*) |
| TAPSE (mm) | 32 ± 5.3 | 28 ± 4.8 | 27 ± 4.8 | 0.0001 | 0.0001 |
| PASP (mmHg) | 51 ± 16 | 43 ± 13 | 49 ± 12 | 0.01 | 0.0001 |
| PASP/CI | 8.1 ± 2.9 | 7.9 ± 3.9 | 11.1 ± 5.0 | 0.001 | 0.016 |
| mPAP (mmHg) | 34 ± 10.0 | 28 ± 8.0 | 32 ± 7.1 | 0.006 | 0.0001 |
| TAPSE/PASP (mm/mmHg) | 0.66 ± 0.2 | 0.71 ± 0.2 | 0.56 ± 0.2 | 0.0001 | 0.059 |
| AccTime (ms) | 127 ± 24 | 118 ± 20 | 110 ± 2 | 0.04 | 0.003 |
| PVR (WU) | 1.73 ± 0.5 | 1.70 ± 0.5 | 1.79 ± 0.5 | 0.8 | 0.2 |
Abbreviations: AccTime, acceleration time; CI, left ventricular cardiac output index; CO, left ventricular cardiac output; E/E’, E wave and E’ wave on TDI ratio; LVEF, left ventricular ejection fraction; LV left ventricular mass; mPAP, mean pulmonary artery pressure; PASP, pulmonary arterial systolic pressure; PVR, pulmonary vascular resistances; RVOT-AccTime, acceleration time on RVOT (right ventricular outflow tract); SV, left ventricular stroke volume; TAPSE, tricuspid annular systolic excursion; TAPSE/PASP, tricuspid annular systolic excursion/pulmonary systolic arterial. (*) no BSA.
Evaluation of hemodynamic parameters at peak exercise tested by mixed model.
| Fixed Factors | Adjustment | ||
|---|---|---|---|
| E/E’ PEAK exercise | Hypertensive status | Gender | 0.2 |
| Age | Therapy | 0.7 | |
| Hypertensive status * Age | E/E’ at baseline | 0.0001 | |
| TAPSE PEAK | Hypertensive status | Gender | 0.0001 |
| Age | Therapy | 0.8 | |
| Hypertensive status * Age | TAPSE at baseline | 0.007 | |
| PASP PEAK | Hypertensive status | Gender | 0.0001 |
| Age | Therapy | 0.002 | |
| Hypertensive status * Age | PASP at baseline | 0.15 | |
| TAPSE/PASP PEAK | Hypertensive status | Gender | 0.0001 |
| Age | Therapy | 0.014 | |
| Hypertensive status * Age | TAPSE/PASP baseline | 0.66 | |
| CO PEAK | Hypertensive status | Gender | 0.6 |
| Age | Therapy | 0.012 | |
| Hypertensive status * Age | CO at baseline | 0.53 |
Abbreviations: CO, left ventricular cardiac output; PASP, pulmonary arterial systolic pressure; TAPSE, tricuspid annular systolic excursion; TAPSE/PASP, tricuspid annular systolic excursion/ pulmonary arterial systolic pressure. * = interaction (hypertensive state and age).